Invert
AI NativeData infrastructure and intelligence for bioprocess.
Est 2021|Valuation $54M|Raised $20.6M
Data infrastructure and intelligence for bioprocess.
Published Jul 14, 2026
The vendor maintains an updates page, but public roadmap granularity is limited.
Source:
An automated domain-trust site assigned the vendor domain a low trust score. Automated domain trust scores are not a reliable indicator of enterprise SaaS legitimacy but may be noted during vendor risk reviews.
Source:
Analyst view: procurement teams should prioritize formal due diligence (SOC 2 report, customer references, security questionnaire responses) rather than automated domain scoring tools.
No traditional customer case study pages with quantified ROI metrics (for example, percentage yield improvement, time saved, or cost savings) were clearly identified on the vendor site in this research window. The vendor provides blog content, product updates, and press releases describing product features.
Sources:
An external design agency (effekt.design) published a case study describing work on the company's branding and communication. This is not a customer success story about the software's technical outcomes but provides an external perspective on marketing and positioning maturity.
Source:
Based on fit for bioprocess data platforms and company stage, likely fit is small-to-mid-sized organizations through larger technical divisions within biotech or bioindustrial sectors. Larger pharma divisions may pilot the product but procurement and validation timelines can be longer.
Get a comprehensive analysis of Invert including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →Source:
Sources:
Sources:
Mainstream B2B review coverage appears limited: no clearly attributable G2, TrustRadius, or Gartner Peer Insights product listing with a meaningful volume of reviews was identified in accessible search results. Searches are often confounded by other companies with the name "Invert".
Attempted but not found:
Sources:
Invert's site includes customer quotes attributed to named individuals. One example is a quote attributed to Mona Mirsiaghi, Director of Fermentation at Inscripta, describing streamlined analysis and management of large bioprocess datasets across platforms and scales.
Source:
Limitations: these testimonials are selected by the vendor and should be treated as directional rather than representative of the broader customer base.
No substantial Reddit or Hacker News discussions specifically about this product were identified in the accessible research window. There is general community discussion noting that products marketed as compliant with Part 11 may still require significant configuration and validation to satisfy auditors; these are not assertions about this vendor specifically but rather about compliance practices more broadly.
Example cautionary thread (not vendor-specific):
Vendor-published performance comparisons for Assist are based on internal evaluations and do not include full public methodology. Vendor testimonials are vendor-selected and are directional rather than representative.
Procurement recommendation: request 2–3 reference calls with customers similar in modality (microbial vs mammalian), scale (lab to pilot to GMP), and regulatory requirements, and request a proof-of-value (PoV) using the organization's historical batch/run data where possible.
Source (vendor claim context):
Decision makers:
End users:
Evidence signals:
Invert is a bioprocess data management, analytics, and modeling software platform for biomanufacturing and bioindustrial process development. The platform's primary function is to consolidate time-series bioprocess data across instruments, scales, sites, and external partners (including CDMOs), and to provide integrated tools for analyzing and modeling that data, including a natural-language analysis interface that produces traceable code.
Key product modules described by the vendor include:
Sources:
Invert targets:
The vendor describes the product as focused on bioprocess use cases and contrasts its approach with:
Sources: